Tectonic Therapeutic, Inc.
No enriched coverage for $TECX in the last 7 days.
Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-
Biotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
Tectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.
Recent TECX coverage spans financial news, earnings and market movers.
In the last 30 days, TECX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($3K). The most active reporter was McNamara Peter, Chief Scientific Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Near-term catalyst path is clearer: TX2100 Phase 1a topline by end of Q3 2026, and TX45 Phase 2 topline early Q1 2027, supported by an IDMC continuation decision.
The catalyst is timeline-based (near-complete enrollment and upcoming topline), which can sustain speculative positioning.
Enrollment completion de-risks trial execution and sets a clear catalyst window for TX45 topline results.
Primarily governance/corporate housekeeping; limited direct fundamental signal, but it confirms board composition and auditor for FY2026.
The inclusion of Tectonic Therapeutic (TECX) in the Russell 3000 index is a positive development, likely to enhance liquidity and investor confidence.
alphai scores every news story that mentions TECX with an AI model for sentiment and relevance, and aggregates insider trades from Tectonic Therapeutic, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-
5 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min readTectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.
4 min readTectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001681087 0001681087 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2
3 min readWATERTOWN, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. ( NASDAQ: TECX ) ( "Tectonic" ) , a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ( ...
2 min readWATERTOWN, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. TECX ( "Tectonic" ) , a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ( GPCRs ) , today ...
2 min readWATERTOWN, Mass., May 17, 2025 ( GLOBE NEWSWIRE ) -- Tectonic Therapeutic, Inc. ( NASDAQ: TECX ) ( "Tectonic" ) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection ...
2 min readData confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ( "PH-HFpEF" )
2 min readThe consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 min read
